the clinical relevance of autoantibodies in scleroderma自身抗体在硬皮病的临床意义.pdfVIP

Arthritis Research Therapy Vol 5 No 2 Ho and Reveille Review The clinical relevance of autoantibodies in scleroderma Khanh T Ho and John D Reveille Division of Rheumatology and Clinical Immunogenetics and General Medicine, The University of Texas–Houston Health Science Center (UTH-HSC), Houston, Texas, USA Corresponding author: John D Reveille (e-mail: john.d.reveille@) Received: 14 November 2002 Revisions received: 14 January 2003 Accepted: 17 January 2003 Published: 12 February 2003 Arthritis Res Ther 2003, 5:80-93 (DOI 10.1186/ar628) © 2003 BioMed Central Ltd (Print ISSN 1478-6354; Online ISSN 1478-6362) Abstract Scleroderma (systemic sclerosis) is associated with several autoantibodies, each of which is useful in the diagnosis of affected patients and in determining their prognosis. Anti-centromere antibodies (ACA) and anti-Scl-70 antibodies are very useful in distinguishing patients with systemic sclerosis (SSc) from healthy controls, from patients with other connective tissue disease, and from unaffected family members. Whereas ACA often predict a limited skin involvement and the absence of pulmonary involvement, the presence of anti-Scl-70 antibodies increases the risk for diffuse skin involvement and scleroderma lung disease. Anti-fibrillarin autoantibodies (which share significant serologic overlap with anti-U3-ribonucleoprotein antibodies) and anti-RNA-polymerase autoantibodies occur less frequently and are also predictive of diffuse skin involvement and systemic disease. Anti-Th/To and PM-Scl, in